Skip to main content
. 2017 Mar 2;11:415–421. doi: 10.2147/PPA.S127508

Table 3.

Adverse reactions reported in patients

Adverse event n (%)
Influenza-like illness 39 (35.5)
Injection site erythema 37 (33.6)
Nodules 14 (12.7)
Lipoatrophy 8 (7.3)
Injection site pain 7 (6.4)
Liver function test abnormal 6 (5.5)
Leukopenia 4 (3.6)
Depression 2 (1.8)
Abscess 2 (1.8)
Skin rash 1 (0.9)
Urticaria 1 (0.9)

Note: Percentages are based on the total number of patients (n=110).